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Cited2 (CBP/p300 interacting transactivator with ED-rich tail 2) is required for embryonic development,
coactivation of transcription factor AP-2, and inhibition of hypoxia-inducible factor 1 transactivation. Cited2
is induced by multiple growth factors and cytokines and oncogenically transforms cells. Here, we show that the
proliferation of Cited2/ mouse embryonic fibroblasts ceases prematurely. This is associated with a reduction
in growth fraction, senescent cellular morphology, and increased expression of the cell proliferation inhibitors
p16INK4a, p19ARF, and p15INK4b. Deletion of INK4a/ARF (encoding p16INK4a and p19ARF) completely rescued
the defective proliferation of Cited2/ fibroblasts. However, the deletion of INK4a/ARF did not rescue the
embryonic malformations observed in Cited2/ mice, indicating that INK4a/ARF-independent pathways are
likely to be involved here. We found that Cited2/ fibroblasts had reduced expression of the polycomb-group
genes Bmi1 and Mel18, which function as INK4a/ARF and Hox repressors. Complementation with CITED2-
expressing retrovirus enhanced proliferation, induced Bmi1/Mel18 expression, and decreased INK4a/ARF
expression. Bmi1- and Mel18-expressing retroviruses enhanced the proliferation of Cited2/ fibroblasts,
indicating that they function downstream of Cited2. Our results provide genetic evidence that Cited2 controls
the expression of INK4a/ARF and fibroblast proliferation, at least in part via the polycomb-group genes Bmi1
and Mel18.
p300 and its paralog, CBP (CREB-binding protein), are
ubiquitously expressed nuclear proteins that function as tran-
scriptional coactivators and histone acetyl transferases, con-
necting DNA-bound transcription factors to the core transcrip-
tional machinery (reviewed in references 19 and 50). p300 and
CBP are essential for normal cardiovascular, neural, and he-
matopoietic development (31, 39, 60). p300 and CBP also play
a fundamental role in cellular growth control (reviewed in
reference 19). Genetic evidence indicates that CBP is a tumor
suppressor. Patients with CBP mutations (Rubinstein-Taybi
syndrome) (41) have a high incidence of neural and develop-
mental tumors (38), and mice lacking a single CBP allele de-
velop hematological malignancies (31). Consistent with this
finding, p300 and CBP function as coactivators of the tumor
suppressor p53 (8, 34). Paradoxically, p300 and CBP are also
required for cell proliferation. Embryonic fibroblasts lacking
p300 proliferate poorly in culture (60), and neutralization of
p300/CBP by antibody injection inhibits progression through
the G1/S transition (1). In keeping with this finding, many
oncogenic transcription factors require either p300 or CBP for
transactivation (reviewed in reference 19).
p300 and CBP also interact with members of the CBP/p300
interacting transactivator with ED-rich tail (CITED) family.
These include CITED1/MSG1 (58); CITED2, splice isoforms
of which are known as p35srj/Mrg1 (12, 33); and CITED4 (15,
59). Loss of Cited2 in mice results in embryonic lethality as a
consequence of cardiac malformations, neural tube defects,
and adrenal gland agenesis (9, 10, 43, 57, 61). At a biochemical
level, CITED2 physically interacts with and coactivates all
transcription factor AP-2 (TFAP2) isoforms and is necessary
for TFAP2 function (9, 14). CITED2 also inhibits hypoxia-
inducible factor 1 alpha (HIF-1) transactivation by disrupting
the HIF-1–p300 interaction (12, 61). These molecular mech-
anisms are thought to underlie the embryonic malformations
observed in mice lacking Cited2. CITED2 is induced by mul-
tiple growth factors and cytokines (e.g., interleukin-1 [IL-1],
IL-2, IL-4, IL-6, IL-9, IL-11, granulocyte-macrophage colony-
stimulating factor, platelet-derived growth factor, and insulin),
and overexpression of CITED2 results in oncogenic cell trans-
formation (51). The response of CITED2 to mitogenic stimuli
and its ability to transform cells suggest that it may function in
cell growth control (51). To understand the genetic pathways
by which CITED2 may control cell proliferation, we studied
mouse embryonic fibroblasts lacking Cited2.
MATERIALS AND METHODS
Mice. Cited2/ and Cited2/ embryos were on a 129Ola/C57BL/6J mixed
background or a C57BL/6J background as indicated and were generated as
previously described (9). Cited2/:INK4a/ARF/ (INK4, inhibitor of cyclin-
dependent kinase; ARF, alternative reading frame) embryos and the relevant
controls (see Fig. 5 and 6) were on an FVB/129Ola/C57BL/6J mixed background
and were generated by intercrossing Cited2/:INK4a/ARF/ mice. INK4a/
ARF/ mice (45) were kind gifts from Ronald DePinho (DFCI, Boston, Mass.).
Mice, embryos, and fibroblasts were genotyped by using PCR with allele-specific
primers (9).
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Fibroblast isolation, passage, growth curves, and colony formation assays.
Murine embryonic fibroblasts were prepared from littermate embryos at 13.5 or
15.5 days postcoitum (dpc) as previously described (36). Adherent fibroblasts
were harvested the following day and plated at a density of 1.5  104 cells per
cm2 (passage 0) and passaged every 3 days thereafter at the same density.
Population doubling per passage was calculated as log(nf/no)/log2, where no is
the initial and nf the final number of cells at each passage (13). When no was
greater than nf, the population doubling was defined as 0. Cumulative population
doubling (CPD) at each passage was calculated by adding population doubling
per passage (13). Senescence-associated -galactosidase was detected as previ-
ously described (17). For growth curves, the indicated number of cells per well of
a 12-well plate were plated and harvested at the indicated time points and
relative cell numbers were measured with crystal violet as previously described
(46). Values were normalized to day 1 for the indicated culture, and each point
was determined in quadruplicate. For colony formation, fibroblasts were plated
at the densities indicated and the colonies were visualized with Giemsa stain as
previously described (13).
Growth fraction. Cells were plated at a density of 1.5  104/cm2 onto glass
coverslips at the indicated passages, and after 48 h, 10 M bromodeoxyuridine
(BrdU) was added for 24 h. The coverslips were fixed, incubated in HCl, and then
stained with anti-BrdU monoclonal antibody (Becton-Dickinson) followed by
secondary sheep anti-mouse fluorescein isothiocyanate-conjugated antibody.
Cells were stained with propidium iodide (PI) and mounted in Vectashield
containing PI (Vector). Nuclear uptake of BrdU and PI was quantitated on a
laser scanning cytometer (CompuCyte, Cambridge, Mass.) and analyzed with
WinCyte software according to the manufacturer’s instructions. Data from the
results for 3,000 to 5,000 cells were acquired for each individual experiment. The
growth fraction was calculated as the percentage of BrdU-positive cells in the
culture.
Retroviruses. CITED2, CITED2, Mel18, Bmi1, and control retroviral super-
natants were generated by using the bicistronic pLZRS-IRES-GFP plasmid and
Phoenix producer cells (gifts from Garry Nolan, Stanford, Calif.). Fibroblasts
were infected as previously described (25). The Bmi1 retrovirus has been de-
scribed previously (25). The Mel18 retrovirus was generated from pSG5-Mel18,
which contains a mouse Mel18 cDNA insert (gift from M. Kanno, Hiroshima,
Japan) with a modified translation start site (GCCACCATGG) that changes the
second amino acid from H to D. We used PCR to convert the Mel18 translation
start site back to the wild-type form (GGCATCATGC) (GenBank accession no.
D90085) and subcloned an EcoRI-SanDI fragment (containing the open reading
frame) into pLZRS-IRES-GFP. Infection efficiencies typically exceeded 80%.
Plasmid vectors were generated by using standard molecular cloning techniques
(7).
Blotting. Northern blotting was performed as previously described (7) by using
6 to 10 g of total RNA (RNeasy Mini-kit, QIAGEN) transferred to Hybond N
membranes (Amersham). 28S and 18S rRNA species were visualized by staining
with 0.05% methylene blue. Murine p19ARF, p19INK4d, and p15INK4b cDNA
plasmids were gifts from Charles Sherr (HHMI, Memphis, Tenn.) and Gordon
Peters (Cancer Research UK, London, United Kingdom). p16INK4a- and
p19ARF-specific probes (INK4a/ARF1 and INK4a/ARF1) were generated from
respective cDNA templates by PCR by using exon-specific primers. Northern
blotting for Mel18, Bmi1, and Mph1 was performed from early passage, non-
confluent mouse embryonic fibroblasts by using the respective murine probes.
The Mph1 probe (IMAGE:3512187) was obtained from MRC-HGMP, Cam-
bridge, United Kingdom. The relative signal intensity was measured by using
NIH Image software on scanned autoradiograms. Western blotting with anti-
Bmi1 monoclonal antibody (229F6; Upstate Biotechnology, Lake Placid, N.Y.),
p16INK4a (M156; Santa Cruz) and anti-p19ARF (Ab80; Abcam, Cambridge,
United Kingdom) polyclonal antibodies, and antitubulin antibody (T-5293;
Sigma) was performed according to the instructions of the manufacturer.
Histology. Embryos were fixed in 4% paraformaldehyde, dehydrated in etha-
nol, and embedded in paraffin wax. Sections (7 m thick) were stained with
hematoxylin and eosin.
RESULTS
Premature proliferation arrest of Cited2/ fibroblasts. We
investigated the proliferative capacity of Cited2/ and Cit-
ed2/ primary mouse embryonic fibroblasts. Fibroblasts were
derived from littermate embryos and passaged every 3 days in
parallel and under identical conditions at a density of 1.5 104
cells/cm2, equivalent to a 3T3 protocol (36). Cited2/ fibro-
blasts proliferated rapidly and then slowed transiently at pas-
sages 5 and 6, following which proliferation was rapid and
continuous (Fig. 1A). Cited2/ fibroblasts proliferated nor-
mally in the first three passages but slowed dramatically and
then arrested permanently. This premature proliferation arrest
was confirmed in three independent experiments by using in-
dependently isolated fibroblasts (data not shown) as well as
fibroblasts isolated from coisogenic mice generated by back-
crossing the Cited2 mutation to the C57BL/6J background for
more than nine generations (Fig. 1B). These results were also
corroborated by plating fibroblasts at passage 3 and assaying
cell growth over the next 14 days without replating (Fig. 1C).
By passage 3, the Cited2/ fibroblasts had a decreased ability
to proliferate in comparison to that of the Cited2/ fibro-
blasts. Cultures of either genotype had indistinguishable spin-
dle-shaped cells at initial plating. With passage, Cited2/ fi-
broblast cultures rapidly accumulated cells that had a flattened
appearance and cytoplasmic enlargement and expressed senes-
cence-associated -galactosidase (17) (Fig. 1D and E).
Reduction in growth fraction. To determine the mechanism
of impaired proliferation in Cited2/ fibroblasts, the fraction
of actively proliferating cells (11) was measured by labeling
parallel cultures with BrdU for 24 h. Bivariate analysis for
BrdU uptake and PI staining showed that the growth fraction
of Cited2/ and Cited2/ fibroblasts was close to 100% when
initially placed in culture (Fig. 2A and B). With serial passage,
the growth fraction of Cited2/ fibroblasts declined more
rapidly than that of Cited2/ fibroblasts. The fall in growth
fraction in the Cited2/ cultures was evident as early as the
first passage. All cultures were initially predominantly diploid,
as determined by PI staining (Fig. 2A). With serial passage,
cultures became tetraploid (Fig. 2A, middle and lower panels).
Although the wild-type culture shown in the top panel of Fig.
2A was still predominantly diploid at this passage, it became
predominantly tetraploid at the next passage (data not shown).
Cited2/ fibroblasts have increased expression of INK4a/
ARF. The above results showed that Cited2/ fibroblasts
cease to proliferate prematurely when cultured, do not spon-
taneously immortalize, and express morphological features of
cellular senescence. Senescence in mouse embryonic fibro-
blasts is associated with increased levels of the alternatively
spliced products of the INK4a/ARF locus, p16INK4a, and
p19ARF (Fig. 3A) (reviewed in references 48 and 49). Members
of the INK4 family function to inhibit cyclin-dependent kinases
4 and 6, whereas p19ARF functions to inhibit MDM2, a repres-
sor of p53. We examined the expression of INK4a/ARF in early
passage Cited2/ and Cited2/ fibroblasts (Fig. 3B through
F). Northern blots were probed with a p19ARF cDNA, which
detects both p16INK4a and p19ARF (Fig. 3A and B) as comi-
grating products. This probe showed that INK4a/ARF expres-
sion was clearly increased (2.7-fold) in Cited2/ fibroblasts
(Fig. 3B). Specific probes that discriminate between the alter-
natively spliced p16INK4a and p19ARF transcripts showed that
the expression of both transcripts was increased (4.2- and 2.7-
fold, respectively) in fibroblasts lacking Cited2 (Fig. 3C and D).
The expression of p15INK4b, a member of the INK4 family (21)
(Fig. 3E), was also increased (2.5-fold) in Cited2/ fibroblasts
(Fig. 3A). We observed no change in the expression of
p19INK4d, another INK4 family member (23) (Fig. 3F). Con-
sistent with these observations, the levels of p16INK4a and
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p19ARF proteins were also increased (2.5- and 2.7-fold, respec-
tively) in Cited2/ fibroblasts at passage 1 (Fig. 3G and H).
Complementation with CITED2 enhances proliferation. To
determine if these changes were specific for loss of Cited2, we
infected Cited2/ fibroblasts with a bicistronic retrovirus ex-
pressing human CITED2 (which is 94% conserved with mouse
Cited2) and GFP (green fluorescent protein) driven by a ret-
roviral long terminal repeat (Fig. 4A). These fibroblasts
showed a marked enhancement of proliferation that was main-
tained for the period studied (i.e., greater than 30 days) and
retained their spindle shape (data not shown). In comparison,
parallel infection with a control GFP-expressing retrovirus
(LZRS) or with retrovirus expressing CITED2, a mutant
lacking the overlapping CBP/p300 and TFAP2 binding do-
mains (9, 12), did not enhance proliferation. These results
were confirmed in two further experiments using indepen-
dently isolated Cited2/ fibroblasts. Infection of Cited2/
fibroblasts with the CITED2-expressing retrovirus also led to a
modest reduction in INK4a/ARF and INK4b expression (1.5-
and 1.6-fold, respectively) (Fig. 4B and C) in comparison to
control retrovirus.
An intact INK4a/ARF gene is essential for proliferation ar-
rest in Cited2/ fibroblasts. The above results suggested that
Cited2 enhances fibroblast proliferation by repressing INK4a/
ARF and/or INK4b. To definitively establish the role of INK4a/
ARF in mediating the premature proliferation arrest of Cit-
ed2/ fibroblasts, we generated fibroblasts lacking both
Cited2 and INK4a/ARF (Cited2/:INK4a/ARF /) and com-
pared their proliferation with that of Cited2/:INK4a/
ARF/, Cited2/:INK4a/ARF/, and wild-type fibroblasts
(Fig. 5A and B). Consistent with previous observations (45),
fibroblasts lacking INK4a/ARF proliferated more rapidly than
wild-type fibroblasts during serial passage in culture, with no
slowing of proliferation for the duration of the experiment (48
days). Consistent with the observations in Fig. 1, Cited2/
fibroblasts arrested prematurely and permanently. Fibroblasts
lacking both Cited2 and INK4a/ARF proliferated almost as
rapidly as those lacking INK4a/ARF, with no slowing of prolif-
FIG. 1. Proliferation properties and morphology of Cited2/ mouse embryonic fibroblasts. (A) Cumulative growth of Cited2/ (w) and
Cited2/ (n) fibroblast cultures prepared from 15.5-dpc embryos on a 129Ola/C57BL/6J mixed background shown as a plot of CPD versus passage
number. (B) These results are also reproduced in Cited2/ (w) and Cited2/ (n) fibroblast cultures isolated from 13.5-dpc embryos on a
coisogenic C57BL/6J background. (C) Proliferative capacity of fibroblasts at passage 3. Fibroblasts prepared from embryos on a 129Ola/C57BL/6J
background were plated in quadruplicate into 12-well plates (6 103 cells per well) and fixed at the indicated time points, and relative cell numbers
were determined by using crystal violet. Data (means  standard errors of the means [SEMs]) were normalized for cell numbers at day 1.
(D) Morphology of Cited2/ (w) and Cited2/ (n) fibroblasts at passage 4. Cited2/ cultures rapidly accumulate cells that appear flat with
cytoplasmic enlargement. (E) Cited2/ (w) and Cited2/ (n) fibroblasts were stained for senescence-associated -galactosidase at passage 1 (P1)
or passage 4 (P4).
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eration. These results were further confirmed in independently
isolated fibroblasts lacking both Cited2 and INK4a/ARF (data
not shown). We then examined the proliferative capacity of
these fibroblasts by plating them at passage 4 and assaying cell
growth over the next 10 days without replating (Fig. 5C). In
keeping with the above observations, Cited2/ fibroblasts had
markedly reduced proliferative ability, and INK4a/ARF/ fi-
broblasts proliferated more rapidly than wild-type fibroblasts.
Fibroblasts lacking both Cited2 and INK4a/ARF proliferated as
rapidly as those lacking only INK4a/ARF. We also examined
the ability of these fibroblasts to form colonies when plated at
low density, an independent measure of the proliferative po-
tential of primary cells (13). In this assay, wild-type and Cit-
ed2/ fibroblasts formed small colonies with very low effi-
ciency (Fig. 5D). INK4a/ARF/ fibroblasts efficiently formed
large colonies. Fibroblasts lacking both Cited2 and INK4a/ARF
formed colonies almost as well as those lacking only INK4a/
ARF. These results indicate that intact INK4a/ARF function is
essential for the reduced proliferative capacity and premature
proliferation arrest observed in Cited2/ fibroblasts.
Elimination of INK4a/ARF does not rescue embryonic mal-
formations in Cited2/ mice. To determine if INK4a/ARF
plays a role in the genesis of embryonic malformations in mice
lacking Cited2, we examined embryos lacking both Cited2 and
INK4a/ARF. Like embryos lacking only Cited2 (9), those lack-
ing both Cited2 and INK4a/ARF had cardiac malformations
(Fig. 6B), adrenal agenesis (Fig. 6D), and exencephaly (Fig.
6F). In these experiments, exencephaly was observed in 4 of 8
embryos lacking Cited2 and 6 of 13 embryos lacking both Cit-
ed2 and INK4a/ARF. Control embryos that were wild type for
Cited2 but lacked INK4a/ARF had normal heart, adrenal, and
neural development (Fig. 6A, C, and E). These results indicate
that Cited2 controls other pathways that are relevant for em-
bryonic development.
Cells lacking Cited2 have reduced Bmi1 and Mel18 expres-
sion. The above data indicated that Cited2 enhances cell pro-
liferation by repressing INK4a/ARF. Genetic evidence indi-
cates that in primary mouse fibroblasts the polycomb-group
gene Bmi1 represses p16INK4a and p19ARF and that Mel18 (a
Bmi1 paralog) represses p16INK4a (25). We therefore exam-
ined the expression of these genes in early passage Cited2/
and Cited2/ fibroblasts derived from littermate embryos. We
found that both Mel18 and Bmi1 expression was reduced (2.3-
and 2.2-fold, respectively) in Cited2/ fibroblasts (Fig. 7A and
B). There was no significant change in the expression of Mph1,
another polycomb group gene. We also examined the fibro-
blasts for TBX2, another INK4a/ARF repressor (24), but ex-
pression of this gene was not detected in wild-type or Cit-
FIG. 2. Growth fraction of Cited2/ mouse embryonic fibroblasts.
(A) Scattergrams of nuclear DNA synthesis (BrdU) vs. DNA content
(PI) of Cited2/ (w) and Cited2/ (n) fibroblast cultures at passages
0 and 4. BrdU-labeled cells are indicated in green. Unlabeled cells are
indicated in blue (2n), red (4n), or black (8n DNA content).
(B) Growth fraction of Cited2/ and Cited2/ fibroblast cultures
plotted against passage number.
FIG. 3. INK4a/ARF expression in Cited2/ fibroblasts. (A) Rep-
resentation of the INK4a/ARF and INK4b locus showing exon structure
and alternative splicing (dashed lines) that generates the three differ-
ent cell cycle inhibitors p15INK4b, p16INK4a, and p19ARF. (B through F)
Northern blots of total RNA obtained from independent pairs of
Cited2/ (w) and Cited2/ (n) fibroblasts derived from littermate
embryos. The passage number (P) is indicated in each panel. (B) A
full-length p19ARF cDNA was used as a probe. This probe detects both
p19ARF and p16INK4a isoforms, which comigrate. (C) p16INK4a was
detected by using a specific exon 1 probe. (D) p19ARF was detected
by using a specific exon 1 probe. (E and F) p15INK4b and p19INK4d
transcripts were detected by using full-length cDNA probes. The bot-
tom section in each panel shows 28S and 18S RNA species, confirming
equal loading. (G and H) Western blots of total cell lysates from
Cited2/ and Cited2/ fibroblasts at passage 1 were probed with
anti-p16INK4a and anti-p19ARF antibodies (top panels) and with an
antitubulin monoclonal antibody (bottom panels) to demonstrate
equal loading.
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ed2/ fibroblasts (data not shown). Infection of Cited2/
fibroblasts with CITED2-expressing retrovirus resulted in a
modest increase in expression of Mel18 (1.5-fold) and Bmi1
(1.4-fold) (Fig. 7C and D).
Bmi1 and Mel18 enhance proliferation of cells lacking Cit-
ed2. The above data indicated that Cited2 is required for nor-
mal Bmi1 and Mel18 expression. To determine if the observed
deficiency of Bmi1 and Mel18 expression in Cited2/ fibro-
blasts would explain their premature proliferation arrest, we
infected Cited2/ and Cited2/ fibroblasts with bicistronic
retroviruses expressing either Bmi1 and GFP, Mel18 and GFP,
or GFP alone (as the control) and performed cell proliferation
and colony formation assays (Fig. 8A and B). Infection with
Bmi1- or Mel18-expressing retroviruses led to enhanced pro-
liferation compared to that for the control retrovirus, regard-
less of the Cited2 genotype (Fig. 8A). The Bmi1 retrovirus
enhanced proliferation better than the Mel18 retrovirus, again
regardless of Cited2 genotype. We next examined the ability of
these fibroblasts to form colonies when plated at low density
(Fig. 8B). Consistent with the above results, infection with
Bmi1- or Mel18-expressing retroviruses led to enhanced col-
ony formation (with Bmi1 being more efficient than Mel18)
compared to that for the control retrovirus, regardless of the
Cited2 genotype. This enhancement of proliferation by Bmi1
and by Mel18 was reproducibly observed in Cited2/ fibro-
blasts obtained from independently harvested embryos. These
results indicate that Bmi1 or Mel18 can enhance the prolifer-
ation of fibroblasts lacking Cited2 and that Cited2 function is
not required for proliferation enhancement by these poly-
comb-group proteins.
DISCUSSION
Normal primary mouse embryonic fibroblasts proliferate
rapidly when explanted but soon slow down in response to the
stress of culture (reviewed in reference 48). This is associated
with cell cycle exit, cytoplasmic enlargement, and expression of
senescence-associated -galactosidase, which are characteris-
tics of cellular senescence (17). At a molecular level in murine
cells, this senescent phenotype is associated with increased
levels of the cell proliferation inhibitors p16INK4a and p19ARF
and activation of the p19ARF target p53 and the p53 target
gene p21CIP1 (reviewed in references 48 and 49). Genetic ev-
idence indicates that intact p19ARF and p53 are necessary for
the senescent phenotype of cultured mouse embryonic fibro-
blasts (45; reviewed in reference 48). Deletion of p19ARF alone
abolishes the senescent phenotype, whereas deletion of
p16INK4a alone does not have this effect, indicating that p19ARF
plays a critical role (28, 30, 47). Notably, the spontaneous
immortalization of wild-type fibroblasts observed when they
are serially passaged in culture typically results from sponta-
neous mutations in p19ARF or p53 (28, 62). Premature senes-
cence of primary fibroblasts is associated with mutations in
genes such as Bmi1, JunD, Atm, and Lig4 that function up-
stream of p19ARF (18, 25, 27, 56). It is also associated with
mutations in Mel18 (25) and Id1 (5), which repress p16INK4a
expression. Overexpression of activated cellular oncogenes
FIG. 4. Complementation of Cited2/ fibroblasts with CITED2.
(A) Cited2/ fibroblasts (derived from an embryo at 13.5 dpc) were
infected with CITED2, CITED2 (lacking residues 215 to 270), or LZRS
(control) retrovirus. Infected fibroblasts were replated on day 7 (passage
0) and passaged every 3 days. Cumulative growth of retrovirally comple-
mented Cited2/ fibroblasts is shown as a plot of CPD versus passage
number. The results were reproduced in two further independent exper-
iments by using independently isolated fibroblasts. (B and C) Northern
blots of total RNA obtained from retrovirally complemented Cited2/
fibroblasts. LZ indicates infection with LZRS (control) retrovirus, and C2
indicates infection with CITED2-expressing retrovirus. The transcripts
detected are indicated in each panel. The bottom panels in each figure
show 28S and 18S RNA species, confirming equal loading. (B) A full-
length p19ARF cDNA was used as a probe. This probe detects both
p19ARF and p16INK4a isoforms, which comigrate. (C) A p15INK4b tran-
script was detected by using a full-length cDNA probe.
FIG. 5. Proliferative properties of fibroblasts lacking both Cited2
and INK4a/ARF. (A and B) Fibroblasts were harvested simultaneously
from independent embryos at 13.5 dpc. Cumulative fibroblast growth is
shown as a plot of CPD versus passage number. Each line represents
fibroblasts isolated from an independent embryo. Fibroblast genotypes
(w, wild-type; n, null) for Cited2 and INK4a/ARF alleles are indicated
in panel B. (C) Proliferative capacity of fibroblasts at passage 4. Fi-
broblasts were plated in quadruplicate into 12-well plates (2.5  104
cells per well) and fixed at the indicated time points, and relative cell
numbers were determined by using crystal violet as previously de-
scribed (25). Data (means  SEMs) were normalized for cell numbers
at day 1. The genotypes are indicated in panel B. (D) Colony formation
assay. Fibroblasts (passage 1) were plated at a density of 4,000 cells per
9-cm plate, and colonies were visualized with Giemsa stain after 7 days.
Fibroblast genotypes are indicated as wild-type (w) or null (n) for
Cited2 and INK4a/ARF alleles, as indicated in panel B.
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such as Ras (37, 46) and MEK (35) in primary cells results in
senescence by activating the p19ARF-p53 pathway.
The results presented here provide genetic evidence that
Cited2, a growth factor and cytokine-inducible gene with on-
cogenic potential (51), is necessary for fibroblast proliferation
in culture. Fibroblasts lacking Cited2 stop dividing prema-
turely, display typical senescent morphology, and express se-
nescence-associated -galactosidase (Fig. 1 and 2). These re-
sults suggested that they are hypersensitive to culture-induced
stress. The expression of p16INK4a, p19ARF, and p15INK4b but
not p19INK4d was markedly increased in Cited2/ fibroblasts
(Fig. 3). These results indicated that Cited2 is required for the
coordinated repression of the physically linked INK4a/ARF
and INK4b genes. INK4a/ARF and INK4b were also repressed
by complementation with CITED2, which also enhanced cel-
lular proliferation, suggesting a causal mechanism (Fig. 4).
Although the reduction of INK4a/ARF and INK4b by retrovi-
rally transduced CITED2 was modest, it was reproducible and
supports the idea that Cited2 represses these genes.
Embryos lacking Cited2 invariably have heart and adrenal
gland defects, and 	50% of embryos have exencephaly (9,
42–44). Premature fibroblast senescence occurred regardless
of the presence or absence of exencephaly (e.g., the mutant
embryos in Fig. 1A and B had normal neural development).
Nevertheless, it was possible that the embryonic heart or ad-
renal malformation itself affects (through secondary changes)
the growth of fibroblasts. To address this issue, we performed
the complementation experiment with CITED2 and showed,
reproducibly, that complementation with retroviral CITED2
markedly enhances proliferation of Cited2/ fibroblasts (Fig.
4A). This effect was specific, as it was not seen with a CITED2
mutant lacking residues 215 to 270. Successful complementa-
tion indicates that no secondary change, e.g., one induced by
the heart, adrenal, or neural defect, was responsible for the
fibroblast growth defect. Thus, the premature senescence ob-
served in fibroblasts lacking Cited2 is indeed specific and is
unlikely to be due to the preexisting embryonic malformation.
FIG. 6. Embryonic malformations in embryos lacking both Cited2
and INK4a/ARF. (A through D) Hematoxylin- and eosin-stained trans-
verse sections from Cited2/:INK4a/ARF/ and Cited2/:INK4a/
ARF/ embryos at 14.5 dpc. Scale bars, 0.1 mm. Axes: d, dorsal; v,
ventral; r, right; l, left. (A) Transverse section through the thorax of a
Cited2/:INK4a/ARF/ embryo shows normal cardiac anatomy. The
interatrial septum (ias) separates the right (ra) and left (la) atria. The
right (rv) and left (lv) ventricles are separated by a normal interven-
tricular septum (ivs) (B) Corresponding section of a Cited2/:INK4a/
ARF/ embryo shows a ventricular septal defect (VSD). (C) Trans-
verse section through the abdomen of a Cited2/:INK4a/ARF/
embryo showing normal right (rad) and left (lad) adrenal glands and
left kidney (lk). (D) Corresponding section of a Cited2/:INK4a/
ARF/ embryo shows lack of right and left adrenal glands. (E and F)
Cranial development in Cited2/:INK4a/ARF/ and Cited2/:
INK4a/ARF/ embryos at 14.5 dpc. Scale bar, 1 mm. (E) Cited2/:
INK4a/ARF/ embryo showing normal cranial development. (F) Cit-
ed2/:INK4a/ARF/ embryo showing exencephaly.
FIG. 7. Expression of Mel18 and Bmi1 in fibroblasts lacking Cited2.
(A) Northern blots of total RNA obtained from Cited2/ (w) and
Cited2/ (n) fibroblasts derived from littermate embryos. The top
panels show blots probed for Mel18, Bmi1, or Mph1, as indicated. Two
Mel18 isoforms are noted (52). The bottom panels show 28S and 18S
RNA species to show equal loading. (B) Western blot of total cell
lysate probed with an anti-Bmi1 monoclonal antibody (top) and re-
probed with an antitubulin monoclonal antibody (bottom) to show
equal loading. (C) Northern blot of total RNA obtained from Cit-
ed2/ fibroblasts infected in parallel with retroviruses. LZ indicates
infection with LZRS (control) retrovirus, and C2 indicates infection
with CITED2-expressing retrovirus. The top panel shows a blot probed
with a Mel18 cDNA. The bottom panel shows 28S and 18S RNA
species to show equal loading. (D) Western blot of total cell lysate
from Cited2/ fibroblasts. LZ indicates infection with LZRS (control)
retrovirus and C2 indicates infection with CITED2-expressing retro-
virus. The experiment was performed in duplicate using independently
isolated Cited2/ fibroblast lines (nos. 1 and 2). The top panel shows
a blot probed with an anti-Bmi1 antibody. The bottom panel shows a
blot probed with an antitubulin antibody to show equal loading.
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Notably, residues 215 to 270 of CITED2 contain the overlap-
ping TFAP2 and CBP/p300 binding domains (9, 12), suggesting
that binding of CITED2 to CBP/p300 and/or TFAP2 is re-
quired for enhancement of cell proliferation.
We also found that deletion of INK4a/ARF completely res-
cued the proliferation defect in fibroblasts lacking Cited2 (Fig.
5). This finding was observed reproducibly in fibroblasts ob-
tained from independently isolated embryos. As the prolifer-
ation defect in Cited2-deficient fibroblasts is reproducibly ob-
served on both mixed (Fig. 1A and Fig. 5A and C) and pure
(Fig. 1B) genetic backgrounds, the reproducible rescue of se-
nescence by deletion of INK4a/ARF in Cited2/ fibroblasts
indicates that random segregation of genetic modifiers in these
experiments does not likely play an important role. Taken
together with the increased levels of INK4a/ARF observed in
Cited2/ fibroblasts and the suppression of INK4a/ARF by
complementation with CITED2, these experiments show that
the elevated levels of INK4a/ARF observed in Cited2/ fibro-
blasts play a major causal role in generating the premature
senescence phenotype and that INK4a/ARF is a critical down-
stream target of Cited2 in fibroblasts. The complete rescue in
cell proliferation that we observed also indicates that no other
downstream mechanism (e.g., the activation of p53 or p27 by a
different mechanism, such as HIF-1 activation in cells lacking
Cited2) is likely to be involved. These results are also sup-
ported by experiments which show that fibroblasts lacking Cit-
ed2 are efficiently immortalized by overexpression of the
p19ARF repressor TBX2 (24) and by antisense p19ARF retro-
virus (16) (K. R. Kranc and S. Bhattacharya, unpublished ob-
servations).
The above data indicated that Cited2 enhances cell prolifer-
ation by repressing INK4a/ARF. However, deletion of the
INK4a/ARF locus did not rescue the embryonic malformations
(cardiac, adrenal, and neural) associated with mutation in Cit-
ed2 (Fig. 6). Thus, the Cited2-mediated repression of INK4a/
ARF observed in fibroblasts does not appear to play a signifi-
cant role in embryonic development. This finding indicates that
Cited2 has two independent functions: first, a role in embryonic
development, and second, a role in fibroblast proliferation
under conditions of culture-induced stress. One possible mech-
anism is that Cited2 positively regulates genes that not only
repress INK4a/ARF but also have independent roles in devel-
opment. Members of the polycomb family (e.g., Bmi1 and
Mel18) are known to play these dual roles (2, 25, 55).
Genetic evidence indicates that in primary mouse fibroblasts
Bmi1 represses p16INK4a and p19ARF and Mel18 represses
p16INK4a (25). Deletion of either Bmi1 or its paralog Mel18
leads to reduced lymphocyte precursor proliferation and pre-
mature proliferation arrest of primary mouse embryonic fibro-
blasts (3, 25). Bmi1 is also necessary for self-renewal of hema-
topoietic stem cells (32, 40). Deletion of INK4a/ARF in mice
lacking Bmi1 rescues premature fibroblast senescence and
postnatal cerebellar and lymphoid defects (25). However,
Mel18 has more complex functions, as evidenced by the fact
that it can also function as a cell proliferation inhibitor in other
cell types (29, 53). Differences in Bmi1 and Mel18 function are
also suggested by distinct phenotypes observed in mutant mice:
for instance, cerebellar defects are observed in mice lacking
Bmi1, and colonic smooth muscle defects are seen in mice
lacking Mel18 (2, 55). Bmi1 and Mel18 function as transcrip-
tional repressors that interact with a similar set of polycomb-
group proteins (6, 20, 22, 26, 54). They function during devel-
opment to repress Hox genes, and deletion of either gene leads
to defects in anteroposterior axis formation (2, 55). Mel18 and
Bmi1 act synergistically in a dose-dependent manner during
development to maintain Hox gene expression and cell survival
(4). Importantly, we have observed anteroposterior patterning
defects in Cited2 mutant embryos. These include fusion of
cranial ganglia (9) and of the cervical vertebrae (S. D. Bam-
forth and S. Bhattacharya, unpublished observations). These
observations prompted us to examine Bmi1 and Mel18 expres-
sion in fibroblasts lacking Cited2.
We found that fibroblasts lacking Cited2 have a marked
reduction in levels of Bmi1 and Mel18 transcripts (Fig. 7).
Complementation of Cited2/ fibroblasts with CITED2 led to
a modest increase in the expression of Bmi1 and Mel18. We
also found that both Bmi1 and Mel18 enhanced the prolifer-
ation of fibroblasts regardless of the Cited2 genotype (Fig. 8),
indicating that Cited2 is not necessary for proliferation en-
hancement by these polycomb-group genes and supporting the
idea that Bmi1 and Mel18 function downstream of Cited2.
However, after infection with Bmi1- and Mel18-expressing ret-
roviruses, Cited2/ fibroblasts proliferated faster than Cit-
ed2/ fibroblasts, implying that Cited2 deficiency cannot be
completely rescued by overexpression of Bmi1 or Mel18 indi-
FIG. 8. Growth properties of Cited2/ and Cited2/ embryonic
fibroblasts infected with Bmi1- and Mel18-expressing retroviruses.
(A) Proliferation of Cited2/ (n) and Cited2/ (w) fibroblasts (de-
rived from littermate embryos on a C57BL/6J background at 13.5 dpc)
infected with Bmi1, Mel18, or control retroviruses. Fibroblasts were
harvested, infected with retroviruses the following day, replated on day
4 (referred to as P0), and passaged in parallel every 3 days at identical
conditions. The proliferation of retrovirally complemented fibroblasts
is shown as plots of CPD versus passage number. (B) Colony formation
assay. Cited2/ and Cited2/ fibroblasts (at passage 6) infected with
the indicated retroviruses were plated at a density of 4,000 cells per
9-cm plate, and colonies were visualized with Giemsa stain after 16
days.
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vidually. One possibility is that other Cited2 functions that are
independent of Bmi1 or Mel18 may be important. Another
possibility is that Cited2 is required for the coordinated induc-
tion of Bmi1 and Mel18, which is not mimicked by the forced
expression of either Bmi1 or Mel18 alone.
In summary, these data indicate that Cited2 is required for
normal Bmi1 and Mel18 expression in primary mouse embry-
onic fibroblasts and that Bmi1 and Mel18 function downstream
of Cited2. The mechanism by which Cited2 induces Bmi1 and
Mel18 is not understood at present. One possibility is that a
coactivation function of Cited2 is required for Bmi1/Mel18
expression. Alternatively, Cited2 may function several steps
away, even perhaps via nonautonomous cell mechanisms, to
control Bmi1/Mel18 expression. These possibilities require fur-
ther investigation. Taken together, our results provide genetic
evidence that Cited2 controls the expression of INK4a/ARF
and fibroblast proliferation at least in part via the polycomb-
group genes Bmi1 and Mel18 and provide a mechanism by
which Cited2 may function as an oncogene.
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